跳至主要内容

Medicilon assists Carephar first potassium-ion-competitive acid blocker "Carenoprazan Tablets" approved for sales in China

 On February 15, the Class 1 new drug Carenoprazan Hydrochloride Tablets, for the treatment of duodenal ulcer and reflux esophagitis, independently developed by Jiangsu Carephar Pharmaceutical (Carephar) was officially approved for sales in market.



Shanghai Medicilon Inc. (Medicilon), as a partner of Carephar, with its solid research and development capabilities, has provided Carenoprazan’s research and development from compound design to preclinical candidate compounds, as well as most of the in vitro H+K+-ATPase testing and other services and the Carenoprazan has been successfully approved.

Medicilon Drug Discovery Services
Open the door to innovative medicine with science and expertise

Drug discovery is the first stage of drug development and a key element that directly affects the success of new drug development.  As a one-stop biopharmaceutical preclinical R&D service platform, Medicilon can provide one-stop service for drug discovery after 19 years of intensive innovation.

Medicilon can undertake different kind of chemistry services such as custom synthesis, compound library construction, SAR compound synthesis and screening, and compound structure and biological activity optimization.  In terms of biology services, Medicilon could provide reparation of hybridoma antibody/genetic engineering antibody, protein expression and purification, X-ray crystal structure analysis/cryo-electron microscopy protein structure analysis, small molecule/antibody drug conjugate/antibody-dependent cell-mediated cytotoxicity detection, organoid drug screening, screening of small molecule inhibitors/agonists targeting enzymes/receptors, protein-protein/protein-small molecule affinity determination, virtual screening and computer simulation-assisted drug design, gene editing and stable cell line construction, CAR-T/CAR-NK construction and target cell killing experiments, M9 selenium medium preparation, as well as research services on the molecular mechanism of drugs.

标签：

评论

发表评论

此博客中的热门博文

Medicilon and Binhui Biopharmaceutical Have Reached a Strategic Collaboration to Jointly Draw a New Blueprint for the Development of New Biological Drugs

  On March 18, Medicilon and Binhui Biopharmaceutical (Binui Bio) announced a strategic collaboration.  The two parties will work together to jointly explore the possibilities in cutting-edge fields such as oncolytic viruses, nucleic acid drugs and protein drugs. Gather and Work Together to Create Advantages      Facilitate the Research and Development of Oncolytic Viruses, Nucleic Acids, Proteins and Other Drugs As a one-stop biopharmaceutical comprehensive preclinical R&D service CRO, Medicilon has been developing and accumulating for 20 years, always adhering to the spirit of innovation, and has successfully constructed bi/multi-specific antibodies,  ADCs ,  mRNA vaccines ,  small nucleic acid drugs ,  PROTAC , and  CGT technical service platform  that have helped 421 INDs obtain clinical approval.  It is this outstanding achievement that has earned Medicilon wide recognition in the industry and laid a solid foundation f...
发表评论
阅读全文

A Nickel-Catalyzed Reductive Alkylation of Aryl Bromides and Chlorides for Sp3-Sp2 Bond Formation

  In 2012, a nickel-catalyzed reductive alkylation method of aryl bromides and chlorides was reported. Under the optimized conditions, a variety of aryl and vinyl bromides as well as active aryl chloride can be reductively coupled with alkyl bromides in high yields. The protocols were highly functional-group tolerant and the reactions were not air or moisture sensitive. The reaction showed different chemoselectivity than conventional cross-coupling reactions. Substrates bearing both anelectrophilic and nucleophilic carbon resulted in selective coupling at the electrophilic carbon (R-X) and no reaction occurred at the nucleophilic carbon (R-[M]). The 2010 Nobel Prize in Chemistry was awarded for the Pd-catalyzed cross-coupling, and in the past decade the progress in cross-coupling has not only had a significant impact on academic research but has also influenced the industrial synthetic application. The transition-metal-catalyzed union of nucleophilic organo-boronic acids with elect...
发表评论
阅读全文

What is Toxicokinetics?

Toxicokinetics  is essentially the study of “how a substance gets into the body and what happens to it in the body”. Four processes are involved in toxicokinetics. The study of the kinetics (movement) of chemicals was originally conducted with pharmaceuticals and thus the term pharmacokinetics became commonly used. In addition, toxicology studies were initially conducted with drugs. However, the science of toxicology has evolved to include environmental and occupational chemicals as well as drugs. Toxicokinetics is thus the appropriate term for the study of the kinetics of all toxic substances. Frequently the terms  toxicokinetics ,  pharmacokinetics , or disposition may be found in the literature to have the same meaning. Disposition is often used in place of toxicokinetics to describe the time-course of movement of chemicals through the body (that is, how does the body dispose of a xenobiotic?). The disposition of a toxicant along with its’ biological reactivi...
发表评论
阅读全文